Date: 2015-06-03
Type of information: Nomination
Compound:
Company: Apogenix (Germany)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On June 3, 2015, Apogenix announced the appointment of Peter Willinger as Chief Financial Officer. As head of the finance division, he will be responsible for the long-term financing of the company to support its continued growth.
Peter Willinger has 15 years of financial management experience in the life sciences and biotech industries. Before joining Apogenix, he was CFO of Lion bioscience AG/Sygnis Pharma AG where he oversaw the finance, investor relations, and corporate development departments. He successfully supported the company’s IPO and contributed to numerous
capital increases. He was further responsible for the strategic realignment and restructuring of the corporation.
Financial terms:
Latest news:
